Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_assertion type Assertion NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_head.
- NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_assertion description "[In each category except for RARS, approximately half of the patients progressed, with a slightly less median time to progression in RAEB-T than for the other subtypes of MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_provenance.
- NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_assertion evidence source_evidence_literature NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_provenance.
- NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_assertion SIO_000772 11960342 NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_provenance.
- NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_assertion wasDerivedFrom befree-2016 NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_provenance.
- NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_assertion wasGeneratedBy ECO_0000203 NP352278.RAYvox_fcMhjbjSwflz2_lIFU_zlSL9jZs_RirVlEbDFM130_provenance.